Essential Thrombocythemia (ET)

           ''Essential thrombocytosis (primary thrombocythemia), first described by Epstein and Goedel in 1934, is a nonreactive, chronic myeloproliferative disorder.
             Essential thrombocytosis (primary thrombocythemia) is associated with sustained megakaryocyte proliferation that increases the number of circulating platelets. Traditionally, essential thrombocytosis (primary thrombocythemia) was considered a clonal disorder that involved pluripotent stem cells; however, studies have indicated that some patients may have polyclonal hematopoiesis''
Extract of Medscape
VIDEOS

Transformation of Essential Thrombocythemia
May 28, 2020, Targeted Oncology

Treating Patients With Essential Thrombocytopenia
March 31, 2020, OncLive

Essential thrombocythemia - causes, symptoms, diagnosis, treatment, pathology
September 30, 2019, Osmose

Essential Thrombocytosis (ET) | Myeloproliferative Neoplasm (JAK2 Kinase)
December 15, 2018, Medicosis Perfectionalis
 
Essential Thrombocythemia for Patients
October 4,  2018, UT Health San Antonio MD Anderson Cancer Center

Current Management of Essential Thrombocythemia - Carlos Besses, MD
December 7, 2017, Cancer Research & Treatment Fund

How Do I Manage My Risk for Clotting As I Age With Essential Thrombocythemia (ET)?
November 30, 2017, Patient Power

Essential Thrombocythemia : Causes, Diagnosis, Symptoms, Treatment, Prognosis
November 18, 2017, Dr. Warraich Health Channel

An Overview of Updated Guidelines in Polycythemia Vera and Essential Thrombocythemia
November 8, 2017, Targeted Oncology

Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia
October 8, 2017, OncLiveTV

Essential Thrombocythemia (ET) in Young People: What’s the Treatment Plan?
October 6, 2017, Patient Power

Topical challenges in the management of ET
August 22, 2017, ImedexCME

What Are Common Symptoms of Essential Thrombocythemia (ET)?
March 17, 2017, Voices of MPN

What Is the Life Span and Quality of Life for a Patient With Essential Thrombocythemia?
December 14, 2016, Patient Power

Is Essential Thrombocythemia (ET) Related to High Blood Pressure?
December 5, 2016, Patient Power

Kate’s 7-Year Journey to ET Diagnosis
October 14, 2015, Patient Power

What is Essential Thrombocythemia?
June 8, 2015, deborah thompkins

The Aim of Essential Thrombocythemia (ET) Treatment
August 23,  2016, Patient Power

Covering Treatment Choices for Essential Thrombocythemia (ET)
February 29, 2016, Patient Power

Essential Thrombocythemia Update 2015
December 16, 2014,  Mayo Clinic

Essential Thrombocythemia Update 2014 - Mayo Clinic
December 17, 2013,  Mayo Clinic

Living with (Primary)Essential Thrombocythemia
August 20, 2012, Thrombocythemia

Essential Thrombocythemia Updates 2012 – Mayo Clinic
March 15, 2012,  Mayo Clinic

Essential Thrombocythemia (2009) - Mayo  Clinic
December 4, 2009,   Mayo Clinic
ARTICLES

Low-Risk Essential Thrombocythemia: A Comprehensive Review
February 2021, HemaSphere

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep
December 28, 2020, NCBI

Expert Reviews the Current State of the Essential Thrombocythemia Treatment Paradigm
September 14, 2020, Targeted Oncology

The new WHO classification for essential thrombocythemia calls for revision of available evidences
February 25, 2020, Blood Cancer Journal

Essential Thrombocythaemia (ET)
June 19, 2019, Leukaemia Foundation

Essential thrombocythemia treatment algorithm 2018
January 10, 2018, Blood Cancer Journal

An Unexpected New Lung Function Has Been Found - They Make Blood
March 24, 2017, Science Alert

Genetic Puzzle Piece for Blood Cancers Found    
December 12,  2013, MedPage Today
 
Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative  Neoplasms
2013, Journal Blood

The Genomic Landscape of Myeloproliferative Neoplasms:  Somatic  CALR Mutations in the Majority of JAK2-Wildtype Patients
2013, Journal Blood
 
Impressive thrombocytosis evolving in a  patient with a BCR-ABL positive CML in major molecular response during dasatinib  treatment unmasks an additional  JAK2V617F
September 5, 2013, Experimental Hematology &  Oncology

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while  in complete cytogenetic remission after treatment with imatinib  mesylate.
June 2013, PublMed      

Inherited predisposition to myeloproliferative neoplasms
May 14, 2013, Therapeutic advances in Hematology
​
Pregnancy and essential  thrombocytemia
March 29, 2011, PublMed Central

New Advances in the Pathogenesis and Therapy of  Essential Thrombocythemia
January 1, 2008, Hematology

Essential thrombocythemia  (Pr Jean Brière – France)
January 8, 2007,  PublMed  Central